LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Lista de Ações・Halozyme Therapeutics Inc

Search

Halozyme Therapeutics Inc

Fechado

SetorSaúde

70.19 -1.57

Visão Geral

Variação de preço das ações

24h

Atual

Mín

70.03

Máximo

72.08

Indicadores-chave
By Trading Economics
Rendimento	292M 150M
Vendas	-75M 377M
P/E Médio do Setor	24.818 49.052
EPS	1.221
Margem de lucro	39.832
Funcionários	423
EBITDA	-63M 218M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+20.03% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	740M 8.4B
Abertura anterior	71.76
Fecho anterior	70.19

Sentimento de Notícias

By Acuity

50%

50%

154 / 344 Ranking em Healthcare

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jun. de 2026, 23:36 UTC

Ganhos

Correction to Oracle Reports Higher 4Q Profit Article

10 de jun. de 2026, 23:19 UTC

Ações em Alta

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 de jun. de 2026, 23:09 UTC

Grandes Movimentos do Mercado

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 de jun. de 2026, 23:04 UTC

Ganhos

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 de jun. de 2026, 20:44 UTC

Grandes Movimentos do Mercado

Caterpillar Raises Quarterly Dividend 8%

10 de jun. de 2026, 23:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Northern Star Should Take No Options Off The Table

10 de jun. de 2026, 23:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 de jun. de 2026, 23:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 de jun. de 2026, 23:47 UTC

Conversa de Mercado

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 de jun. de 2026, 23:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 de jun. de 2026, 23:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 de jun. de 2026, 23:32 UTC

Conversa de Mercado

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 de jun. de 2026, 23:20 UTC

Conversa de Mercado

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 de jun. de 2026, 22:05 UTC

Conversa de Mercado

Correction to Bank of Canada Stays on Hold Market Talk

10 de jun. de 2026, 21:57 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:52 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:35 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:22 UTC

Ganhos

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

10 de jun. de 2026, 20:39 UTC

Conversa de Mercado

Ganhos

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 de jun. de 2026, 20:34 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

Ganhos

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

10 de jun. de 2026, 20:33 UTC

Conversa de Mercado

Ganhos

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

20.03% parte superior

Previsão para 12 meses

Média 85.8 USD 20.03%

Máximo 96 USD

Mínimo 70 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

3

Comprar

2

Manter

0

Vender

Com base em 5 analistas que deram avaliações de ações para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

154 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Outras ações do setor

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat